CNS Lymphoma Clinical Trial
Official title:
Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma
Zanubrutinib is a novel BTK inhibitor with proven activity in patients with various B-cell lymphomas addicted to the B-cell receptor signaling pathway.
Studies involving gene expression profiling and next generation sequencing have demonstrated that CNS lymphomas mostly are of the ABC-subtype and harbor mutations that reinforce BCR signaling. Ibrutinib, as the first BTK inhibitor, showed substantial activity in patients with R/R PCNSL and R/R SCNSL. Zanubrutinib is a novel BTK inhibitor with proven activity in patients with various B-cell lymphomas addicted to the B-cell receptor signaling pathway. In addition, pharmacological studies demonstrated the free drug exposure of zanubrutinib at 160 mg BID is roughly 10 times that of ibrutinib at 560 mg QD, and penetration into the CNS by zanubrutinib and ibrutinib is similar, suggesting the potential activity of zanubrutinib in the treatment of CNS lymphomas. However, the outcome of R/R PCNSL and R/R SCNSL patients treated with zanubrutinib monotherapy is still unclear. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT05222269 -
[68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients
|
Phase 2 | |
| Recruiting |
NCT06132737 -
[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients
|
Phase 1/Phase 2 | |
| Terminated |
NCT05242146 -
GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma
|
Phase 1 | |
| Completed |
NCT01319591 -
Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate
|
||
| Recruiting |
NCT06322342 -
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
|
Phase 2 | |
| Recruiting |
NCT05351593 -
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05828628 -
CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study
|
||
| Completed |
NCT01182415 -
High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma
|
Phase 2 | |
| Not yet recruiting |
NCT06343311 -
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04841434 -
A Phase I/II Study to Investigate the Use of VORAXAZE™ as Intended Intervention in Patients With CNSL
|
Phase 1/Phase 2 | |
| Completed |
NCT01083342 -
High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study
|
Phase 2 | |
| Completed |
NCT05293990 -
Usefulness of Gadovist-enhanced FLAIR Imaging
|
N/A | |
| Completed |
NCT00596154 -
Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05926427 -
Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement
|
Phase 2 |